Adverse effects of levodopa/carbidopa intrajejunal gel treatment: a single center long-term prospective study

Background:Levodopa/carbidopa intrajejunal gel (LCIG) is an efficient therapeutic strategy to overcome motor fluctuation in advanced Parkinson’s disease (PD). However, it requires invasive percutaneous endoscopic gastrojejunostomy (PEG) and is associated with several adverse effects (AE). In this study, we evaluated PEG-related, device-related and other AE in a well-defined prospective cohort of PD patients.